A Look at Galil Medical
The New Vision of Precision
Galil Medical is leading a new era of minimally invasive cryotherapy solutions that enhance patient quality of life. Since its foundation, Galil Medical has dedicated extensive research toward increasing the ease of use and precision of cryotherapy and minimally invasive procedures in order for physicians to provide patients with rapid recovery times and a high quality of life.
Galil Medical’s technology, adopted originally from military applications, involves freezing and ablating diseased tissue in a technique referred to as cryotherapy, also referred to as cryoablation and cryosurgery. The core technology is based on the Joule-Thomson effect (JT), in which compressed gas causes significant and fast temperature changes.
Galil Medical cryotherapy systems use compressed Argon gas to produce extremely low temperatures. As the gas passes through the cryoablation needle, the tip of the needle is cooled, forming an iceball, which engulfs the tumor and destroys the tissue. A variety of needle types is available to sculpt a freeze zone conformed to the tumor size and shape. Galil Medical cryosurgical systems precisely deliver sub-zero temperatures to target tissue with the aid of patented 17-gauge cryoablation needles and high-resolution imaging for the cryosurgical ablation of benign and cancerous tumors. The integration of high resolution imaging with ultrasound, CT, or MR enables a high level of control for needle placement and positioning, iceball formation in real-time and the freezing process during minimally invasive surgery.
Cryotherapy ablation has been widely used for prostate cancer treatment and kidney cancer treatment. New ablation treatments for various other tumors are being developed in the Women’s Health and Interventional Radiology markets.
A Focus on Innovation
A strong commitment to technological innovation has enabled Galil Medical to develop and manufacture the smallest diameter cryoablation needles available in the market (1.47 mm) while maintaining high power cryosurgery (freezing) and thawing capabilities. In addition, the company’s multi-point thermal sensors (MTS) provide continuous, real-time temperature monitoring throughout the gland, or tumor, to verify lethal temperatures within target tissue while controlling impact to surrounding healthy tissue during cryosurgical treatments.
R&D and manufacturing facilities are based in Yokneam, Israel, and dedicated sales offices are located in Arden Hills, Minnesota, United States and London, England. Shareholders include Thomas, McNerney & Partners, Vertical Group, and Investor Growth Capital.